Table 2.
Treatment and outcome of control and HA group (Cytosorb™-group)
| Outcome measure | Control group (N = 33) | Cytosorb™-group (N = 43) | p value |
|---|---|---|---|
| ICU mortality rate | 66.7% (22/33) | 72.1% (31/43) | |
| O/E ratio ICU mortality | 0.81 (0.65–0.94) | 0.82 (0.72–0.93) | |
| Hospital mortality rate | 66.7% (22/33) | 76.7% (33/43) | |
| O/E ratio hospital-mortality | 0.81 (0.65–0.94) | 0.88 (0.77–0.99) | |
| LOS ICU (days [d]) | 21 (6, 54) | 12 (3, 23) | 0.026 |
| LOS ICU for survivors (d) [N = 11 vs 12] | 64 (45, 80) | 29 (20, 40) | 0.006 |
| LOS ICU for non-survivors (d), [N = 22 vs 31] | 10 (4, 20) | 7 (3, 14) | 0.115 |
| LOS hospital (d) | 25 (11,71) | 15 (5,30) | 0.040 |
| LOS hospital survivors (d) | 86 (68, 122) | 52 (38, 45) | 0.004 |
| LOS hospital non-survivors (d) | 13 (5, 28) | 8 (5, 17) | 0.096 |
| Length of ventilatory support (d) | 19 (5, 41) | 8 (3,17) | 0.009 |
| Length of ventilatory support for survivors (d) | 42 (37, 72) | 20 (11, 26) | 0.001 |
| Length of ventilatory support non-survivors (d) | 10 (4, 20) | 6 (3, 13) | 0.121 |
| Length of CVVHDF (d) | 6 (3, 16) | 3 (2, 7) | 0.012 |
| Length of CVVHDF survivors (d) | 12 (4, 19) | 6 (3, 10) | 0.260 |
| Length of CVVHDF non-survivors (d) | 4 (2, 10) | 2 (2, 4) | 0.047 |
| Length of catecholamine administration (d) | 18 (7, 30) | 8 (3, 13) | 0.001 |
| Length of catecholamine administration survivors (d) | 29 (21, 47) | 10 (7, 12) | > 0.001 |
| Length of catecholamine administration non-survivors (d) | 11 (4, 20) | 7 (3, 13) | 0.043 |
ICU intensive care unit, CVVHDF continuous veno-venous haemodiafiltration